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Abstract 
Background and purpose:  
This study evaluated the use of total lesion glycolysis (TLG) determined by different automatic segmentation 
algorithms, for early response monitoring in non-small cell lung cancer (NSCLC) patients during concomitant 
chemoradiotherapy. 
Materials and Methods: 
Twenty-seven patients with locally advanced NSCLC treated with concomitant chemoradiotherapy underwent 
18
F-
fluorodeoxyglucose (FDG) PET/CT imaging before and in the second week of treatment. Segmentation of the 
primary tumours and lymph nodes was performed using fixed threshold segmentation at (i) 40% SUVmax (T40), (ii) 
50% SUVmax (T50), (iii) relative-threshold-level (RTL), (iv) signal-to-background ratio (SBR), and (v) fuzzy locally 
adaptive Bayesian (FLAB) segmentation. Association of primary tumour TLG (TLGT), lymph node TLG (TLGLN), 
summed TLG (TLGS=TLGT+TLGLN), and relative TLG decrease (ΔTLG) with overall-survival (OS) and progression-free 
survival (PFS) was determined using univariate Cox regression models.  
Results:  
Pre-treatment TLGT was predictive for PFS and OS, irrespective of segmentation method used. Inclusion of TLGLN 
improved early response assessment, with pre-treatment TLGSmore stronglyassociated with PFS and OS than 
TLGTfor all segmentation algorithms. This was also the case for ΔTLGS, which was significantly associated with PFS 
and OS, with exception of RTL and T40. 
Conclusions: 
ΔTLGS was significantly associated with PFS and OS, except for RTL and T40. Inclusion of TLGLN improves early 
treatment response monitoring during concomitant chemoradiotherapy with FDG-PET. 
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Introduction 
Non-small cell lung (NSCLC) cancer remains a disease with a generally poor prognosis [1]. At the time of 
diagnosis, one third of patients with NSCLC presents with locally advanced non-metastatic disease [1]. 
For these patients, radiotherapy in combination with chemotherapy is the accepted standard of care. 
With the aim of improving patient outcome, combined and intensified treatment approaches are 
increasingly being investigated. However, not all patients equally benefit from these treatment 
approaches and rational selection of available treatment options in a personalized medicine framework 
is required[2]. 
Positron emission tomography (PET) in combination with X-ray computed tomography (CT) with the 
glucose analogue 18F-fluorodeoxyglucose (FDG) has proven to be a valuable tool to personalize 
treatment for this patient group[2]. Firstly, incorporation of FDG-PET images into the radiotherapy 
planning algorithm improves definition of gross tumour volume (GTV)[3-5] and might facilitate the 
concept of selective nodal irradiation[6]. Secondly, it has been shown that FDG-PET can identify areas 
that are at risk of local relapse[7, 8], permitting to use the concept of molecular imaging-based dose 
painting[9]. Thirdly, several studies emphasize the ability of FDG-PET to monitor therapy response at an 
early treatment stage using quantitative PET indices [10-14]. Early response monitoring during 
treatment can facilitate clinical decision-making and improve patient management through avoidance of 
unnecessary side effects and costs of ineffective treatment.  
However, employing the concept of FDG-PET-guided treatment decisions requires robust and 
standardized methods to derive these quantitative indices from PET images. Particularly, the strong 
dependence of most image-derived response indices on quantification of these volumes emphasizes the 
need for standardized and consistent determination of lesion volume in PET images. In this regard, there 
has been a widespread interest in the development for automated segmentation algorithms for PET. 
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Over the years, there has been a rapid growth of segmentation algorithms for PET reported in literature 
[15], aŶ eveŶt ǁhiĐh is also referred to as ͚yapetism͛ ;͞yet aŶother PET segŵeŶtatioŶ ŵethod͟Ϳ [16]. 
Difficulties encountered by these algorithms for automatic lesion segmentation in PET images are local 
contrast variations due to heterogeneous FDG uptake in the lesion, adjacent FDG-avid anatomy and 
lymph nodes, and relatively high noise content of PET images, often rendering the task of automatic 
lesion delineation challenging [15]. This becomes even more difficult when automatic segmentation has 
to be performed on low contrast interim and end-of-treatment PET images, where radiotracer uptake 
can be considerably reduced due to therapy effects. However, up until this day there is no standardized 
method for automatically determining lesion volume on PET images and many studies consider different 
segmentation algorithms for this purpose [17, 18]. The purpose of this study was to evaluate this clinical 
applicability and performance of several established segmentation algorithms for generating plausible 
segmentation volumes that can be applied specifically to predict therapy response during treatment for 
patients with locally advanced stage IIIA or IIIB NSCLC treated with concomitant chemoradiotherapy. 
The predictive value of total lesion glycolysis (TLG), as determined by these different algorithms, for 
early response assessment during concomitant chemoradiotherapy was evaluated. 
 
Materials and methods 
Patients 
A total of 27 patients with newly diagnosed NSCLC stage IIIA or stage IIIB were prospectively included in 
this study, as described before [10]. Patients were treated with concomitant radiotherapy and 
chemotherapy. This study was approved by the institutional review board (IRB) of the Radboud 
university medical center. Written informed consent was obtained from every patient. Patient 
characteristics are summarized in Table 1.  
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Treatment and follow-up 
Intensity modulated radiotherapy (IMRT) was performed (10 MV photons), consisting of 33 fractions of 
2 Gy (5 fractions a week for 6 week and 3 days) resulting in a total dose of 66 Gy on the primary tumor 
and affected lymph nodes (i.e. pathologically proven or FDG-avid lymph nodes). Chemotherapy 
consisted of two cycles of cisplatin 50 mg/m2 intravenously (day 1, 8, 22, and 29) and etoposide 100 
mg/m2 intravenously (day 1-3, and day 22-24). Median overall treatment time was 45 days (range 43-48 
days). Patients with progressive disease during follow-up received palliative treatment. Follow-up during 
and after treatment consisted of clinical examination at regular intervals. When residual or recurrent 
disease was suspected, chest X-ray and chest CT-scans were performed. For each patient, sequential 
FDG-PET/CT imaging was performed before and during treatment. The pre-treatment scan was obtained 
before treatment (median 11 days, range 1-28 days) while interim FDG-PET imaging was performed in 
the second week during concomitant treatment (median 14 days, range 13-16 days), always before the 
second cycle of chemotherapy after 20 Gy radiotherapy. According to the treatment protocol all 
patients started with radiotherapy at the first day of the first cycle of chemotherapy, i.e. no neo-
adjuvant treatment was applied. 
Patient preparation and FDG PET imaging 
Imaging was performed using a hybrid Biograph Duo PET/CT scanner (Siemens Medical Solution, 
Knoxville, TN, USA). The PET scanner was accredited by the Research 4 Life (EARL) initiative for 
quantitative FDG-PET/CT studies [19]. Before image acquisition, patients fasted for at least six hours and 
blood glucose levels were lower than 8.2 mmol·L-1 in all patients. The amount of activity administered to 
the patieŶt ǁas adjusted to the patieŶt͛s ǁeight aŶd ǁas ϯ.ϰϱ MBƋ·kg-1. Details regarding the PET 
acquisition protocol are summarized in table 1.For the purpose of attenuation correction and 
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anatomical reference, a low dose (LD) CT scan was acquired with a reference tube current time product 
of 40 mA·s. LDCT scans were acquired during timed unforced expiration breath-hold. Modulation of X-
ray tube current was performed using CARE Dose 4D. Reconstruction of PET images was performed with 
a 2D ordered subset expectation maximization (2DOSEM) algorithm using a matrix size of 128×128, 4 
iterations and 16 subsets. Post reconstruction filtering was performed using a three-dimensional 
Gaussian filter kernel with a full width half maximum of 5 mm.  
Image segmentation 
The primary tumour and FDG positive lymph nodes were delineated on the pre-treatment and interim 
PET images. Firstly, delineation was performed using a fixed threshold region growing segmentation at 
40% (T40) and 50% (T50) of the maximum standardized uptake value (SUVmax) value. Furthermore, 
adaptive threshold algorithms were used for image segmentation. These included the iterative relative-
threshold-level (RTL)[20]  and signal-to-background ratio (SBR)[21]  approach. For the SBR method, the 
background for segmentation of the primary tumour was defined by placing a volume of interest (VOI) in 
parenchyma of the contra-lateral lung. For lymph node segmentation, the background was defined by 
placing a VOI near the aortic root in the mediastinum. The seed-point for the T40, T50, RTL, and SBR 
segmentation was the SUVmax voxel of either the primary tumour (SUVT,max) or the corresponding lymph 
nodes (SUVLN,max). The threshold-based segmentations were performed using the Inveon Research 
Workplace (IRW) 4.1 Software (Preclinical Solutions, Siemens Medical Solutions USA, Knoxville 
Tennessee, USA). In addition to threshold-based segmentation, image segmentation was performed 
using the fuzzy locally adaptive Bayesian (FLAB) algorithm [22]. Segmentation with this algorithm is 
performed using custom in-house developed software (ImageD, LaTIM Université de Bretagne 
Occidentale, Brest, France). The number of classes for segmentation was limited to two and parameters 
were automatically determined by the software.  
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Image analysis 
The TLG of the primary tumour (TLGT), defined as the product of the mean tumour FDG uptake 
(SUVT,mean) and metabolic tumour volume (MTV), was calculated on the pre-treatment and interim PET 
images. Similarly, lymph node TLG (TLGLN) was defined as the mean uptake of the lymph nodes 
(SUVLN,mean) and the corresponding metabolic volumes of the lymph nodes. Furthermore, a summed TLG 
(TLGS=TLGT+TLGLN was calculated. Evaluation of therapy response was performed by calculating the 
fractional decrease in TLG between pre-teatment and interim PET images (ΔTLG). Segmentation 
performance of the different algorithms was evaluated through visual assessment by a nuclear medicine 
physician experienced in thoracic imaging. Segmentation failures were visually identified andwere 
defined as the propagation of segmentation into other anatomical structures, or premature termination 
of the algorithm resulting in only partial segmentation of the primary tumour and lymph nodes. Lesions 
that could not be properly segmented according to these criteria were omitted from the analysis. In 
addition, similarity between MTVs obtained with different segmentation algorithms  was quantified by 
calculating the spatial overlap using a generalization of the Jaccard index (JI), as described in equation 1. 
                                          
 
Here the numerator           denotes the intersection between segmented volumes (in this 
study, five in total), while the denominator           represents the union of the segmented 
volumes. Perfect spatial overlap is indicated by a value for the JI of 1.0, whilst a value of 0 indicates no 
spatial overlap of the volumes. 
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Clinical outcome and statistical analysis 
Statistical analysis was performed using SPSS Statistics 20 (IBM, Armonk, New York, USA) and GraphPad 
Prism, version 4.0c (GraphPad Software Inc, La Jolla, California, USA). Patient outcome data for time to 
progression was defined as the interval between the start of treatment and the date of documented 
disease progression as confirmed by imaging or biopsy. If a patient was progression free at the closeout-
date (January, 2015), time to progression was censored to that date. PFS was measured from the date of 
treatment start to the date of documented disease progression. Similarly, if patients were still alive at 
the closeout-date, patients were censored for OS. The predictive value of pre-treatment TLG and ΔTLG 
were determined for different segmentation algorithms using univariate Cox regression models. 
Correlation between the MTVs and TLGs of different segmentation algorithms was calculated using 
Spearman rank correlation. Statistical significance was defined for p<0.05. 
 
Results 
 
The median follow-up time for this patient population was 23.4 months (range 3.5 – 61.9). During 
follow-up eighteen patients died, all related to cancer progression. Three patients were lost during 
follow-up. A total of twenty patients developed recurrent disease during follow-up; seven patients 
developed progression of local disease, while metastases were seen in 13 patients. Median time to 
disease progression was 21 months. PFS after study-baseline at 1 year was 63% (17 out of 27).  
 
Of the 27 patients, 25 had a visible primary tumour. For the other two patients, there was no 
radiological evidence for a primary tumour (i.e. cT0). The smallest pre-treatment MTVs were obtained 
when segmentation was performed with the T50 segmentation algorithm (24.7 ± 30.8 mL), compared to 
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T40 (34.8 ± 39.1 mL), SBR (38.7 ± 42.4 mL) RTL (30.7 ± 34.0 mL). Segmentation with FLAB resulted in the 
largest MTVs (42.3 ± 42.1 mL). Interim PET MTVs showed similar trends with the smallest MTV for the 
T50 (20.8 ± 32.6 mL) method, followed by T40 (31.6 ± 44.6 mL), RTL (26.8 ± 37.0 mL), SBR (36.2 ± 50.2 
mL) and FLAB (37.6 ± 48.2 mL).  For the pre-treatment PET images, excellent correlation was found 
between delineation methods for MTV (range ρ Ϭ.ϵ7 – 1.0, p < 0.0005), TLGT (range ρ Ϭ.ϵ5 – 1.0, p < 
0.0005) and SUVmean (range ρ Ϭ.ϵ8 – 1.0, p < 0.0005). Similarly, for in-treatment PET images, an 
excellent correlation was found between delineation methods for MTV (range ρ Ϭ.ϵ3 – 1.0, p < 0.0005), 
TLGT (range ρ Ϭ.ϵ4 – 1.0, p < 0.0005) and SUVmean (range ρ Ϭ.ϵ4 – 1.0, p < 0.0005). 
Quantitative and visual analysis of the MTVs obtained with different segmentation algorithms revealed 
that the MTVs were highly similar regarding shape and spatial overlap. Furthermore, the algorithms 
revealed a similar trend in SUVT,mean and MTV change between pre-treatment and interim FDG-PET 
(supplementary data). The T50 volumes were always completely enveloped by the other volumes. The 
generalized JI for all MTVs on the pre-treatment and interim PET was 0.58 ± 0.13 (range 0.31 – 0.78) and 
0.53 ± 0.16 (range 0.20 – 0.86). When the T50 volumes were omitted from the analysis, the mean JI for 
pre-treatment and interim PET volumes was 0.74±0.12 (range 0.46 – 0.89) and 0.71 ± 0.14 (range 0.47 – 
0.96). In tumours with heterogeneous FDG uptake, the T50 algorithm yielded contours that were more 
erratic and sensitive to discontinuities within the tumour, while FLAB, SBR, RTL, and T40 algorithms 
would segment patches with FDG-uptake continuously throughout the entire lesion, giving an improved 
representation of the total volume with FDG-uptake.  
In the pre-treatment PET images, FLAB segmentation resulted in one segmentation failure of the 
primary tumour in one patient due to small size and low contrast. In this patient, all segmentation 
methods failed to segment the primary tumour in the interim PET images. Furthermore, the T40, T50, 
RTL, and SBR methods failed to segment the primary tumour in an additional patient that was 
presenting with a large lesion with extended growth into the central mediastinum on interim PET 
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images. The FLAB algorithm could segment the primary tumour in this patient and did not show 
uncontrolled propagation of segmentation into the mediastinal background. 
Of the 27 patients, 18 patients had FDG positive lymph nodes on the pre-treatment PET images. Given 
the smaller volumes and in general lower contrast of mediastinal and hilar lymph nodes, there were 
considerably more segmentation failures when performing automatic segmentation of lymph nodes. 
The T40 and RTL algorithms failed to segment 14 and 17 of the 41 lymph nodes on the pre-treatment 
PET images, respectively. The number of segmentation failures for the T50 and FLAB algorithms in the 
pre-treatment PET images was 9 and 8, respectively. The SBR algorithm had the fewest segmentation 
failures, with only 6 lymph nodes segmentation failures in the pre-treatment PET images. 
Reduction of lymph node contrast owing to therapy effects on the interim PET images resulted in more 
segmentation failures for the T40, T50, RTL and FLAB algorithms. Of the 41 lymph nodes in the interim 
PET, there were 24 segmentation failures for the T40 and RTL algorithms. For the T50 and FLAB method, 
12 and 14 lymph node segmentation failures occurred in the interim PET, respectively. Similar to the 
pre-treatment PET, the SBR algorithm had the fewest segmentation failures, with 5 segmentation 
failures. Failure of lymph node segmentation was usually due to uncontrolled propagation of the 
segmentation algorithm in the mediastinal background or primary tumour. Figure 1 depicts the TLGS on 
pre-treatment and interim PET images in box whisker plots. 
Pre-treatment SUVT,max, interim SUVT,max, and relative decrease in SUVT,max of the primary tumour was 
not significantly predictive for PFS and OS. Similarly, pre-treatment SUVT,mean, interim SUVT,mean, and 
relative decrease in SUVT,mean of the primary tumour was not significantly predictive for PFS and OS in 
this cohort. However, pre-treatment TLGT was significantly associated with PFS and OS for all 
segmentation methods. The ΔTLGT was significantly predictive with PFS for all methods except for FLAB. 
Furthermore, ΔTLGT was significantly associated with OS for the T50 and SBR methods. Hazard ratios 
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(HRs) and corresponding 95% confidence interval (CI) of  TLGT and ΔTLGT in the univariate Cox regression 
analysis for PFS and OS are summarized in table 2. 
 
Only TLGLN obtained with the SBR and T50 methods was significantly predictive for PFS and OS. 
Furthermore, inclusion of TLGLN improved early response assessment using PET, with pre-treatment TLGS  
more strongly associated with PFS and OS than TLGT. Figure 2 depicts differences in PFS and OS of two 
patients ǁith a differeŶt lyŵph Ŷode respoŶse, as refleĐted ďy ΔTLGS. 
The differences in lymph node segmentation performance was reflected in the significance of TLGS 
measurements in the univariate analysis. The HRs and corresponding 95% CI of TLGS and ΔTLGS in the 
univariate Cox regression analysis for PFS and OS are summarized in table 3. 
 
Discussion 
In this study we showed that TLG is a robust metric to monitor therapy response in patients undergoing 
concomitant chemoradiotherapy for locally advanced NSCLC. Furthermore, inclusion of TLGLN improves 
early assessment of treatment response in this patient population. Results of this study are in line with 
available data in literature and emphasize the role of FDG-PET imaging for early response monitoring 
NSCLC [10-14]. In particular, TLG outperformed the more traditional SUVT,max and SUVT,mean for predicting 
PFS and OS. This is probably due to the fact that TLG contains information about disease load as well as 
metabolic activity of involved lesions.  
In general, all segmentation algorithms had a similar performance for segmenting the primary tumour in 
different anatomical locations. The presence of adjacent anatomical structures (e.g. lymph nodes, 
mediastinum, liver), did not result in large differences in segmentation performance. Furthermore, 
lower contrast of the interim PET images resulted in a very limited increase in the number of 
segmentation failures. Absolute differences in TLG obtained by the different segmentation methods did 
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not influence its predictive value. . Due to the limited size and lower contrast, there were considerably 
more lymph node segmentation failures. The number of lymph node segmentation failures increased in 
the interim PET images owing to further reduction in image contrast. Nevertheless, adequate lymph 
node segmentation is of importance, with TLGS having a stronger association with PFS and OS. Out of all 
the segmentation algorithms, the SBR method demonstrated the lowest number of segmentation 
failures. The number of FLAB lymph node segmentation failures could be reduced by using a supervised 
input, with an equal performance to that of the SBR method, which is in line with results from another 
study [23]. However, in view of standardizing response measurements, such a user dependency should 
be avoided and we chose only to include the results of automatic FLAB segmentation. 
Although the results emphasize that PET could be used for prediction of early treatment response in 
patients with locally advanced NSCLC treated with concomitant chemoradiotherapy, employment of 
PET-guided decisions for personalizing treatment was not explored. Particularly, the strong association 
of pre-treatment TLG with PFS and OS might merit the choice for treatment intensification in patients 
with a high pre-treatment TLG such as proposed in the PET-boost dose-escalation trial[24]. Furthermore, 
one might also consider treatment intensification when interim PET images demonstrate a limited 
decrease in TLG, for instance by dose escalation to metabolically active sub volumes the primary 
tumour[25, 26], in order to improve loco-regional tumour control. However, standardizing PET-based 
dose painting approaches is of utmost importance. This is emphasized in a study by Knudtsen et al. 
where the used PET reconstruction algorithm and choice of segmentation thresholds significantly 
influenced treatment plans incorporating these dose painting concepts [27]. Although threshold-based 
segmentation is frequently used for defining sub volumes for dose painting, stability of different 
algorithms under varying imaging conditions for this purpose has yet to be investigated. Interestingly, 
studies emphasize that there is a high stability of FDG uptake in tumour areas during the course of the 
treatment that can be identified on pre-treatment FDG-PET images[28]. Although useful, interim PET 
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imaging in a molecularly image-guided ART (IGART) setting would still be of great interest to monitor 
changes during radiotherapy [2]. Indeed, employment of IGART using FDG-PET has been shown to be of 
potential value, where the GTV is adapted according to interim FDG-PET imaging[2].Furthermore, results 
from a study conducted by Nygård et al. emphasize that FDG-PET might identify lesion-specific response 
after a single series of chemotherapy in NSCLC and could be a useful addition to guide and individualize 
radiotherapy strategy [29]. Although dose redistribution might be useful for improving loco-regional 
tumour control, systemic disease control is also an important aspect in this patient group [30]. In this 
setting, interim PET imaging might identify failure of systemic disease control at an early stage (i.e. 
detection of additional lymph node or distant metastasis), making it possible to adapt treatment 
accordingly. 
A limitation of the current study is that only a small patient cohort was considered. However, the 
advantage is that TLG measurements using different automatic segmentation algorithms showed 
consistent results, with most algorithms yielding TLG values that had a similar predictive value in this 
patient cohort. 
This study emphasizes that adequate lymph node segmentation in PET images improves assessment of 
early treatment response in NSCLC patients treated with concomitant chemoradiotherapy. In this 
regard, given the relatively ease of implementation and the high number of successful lymph node 
segmentations, SBR is the method of choice for calculation of TLG in FDG-PET images of patients with 
locally advanced NSCLC for the purpose of assessment of early treatment response. 
 
Acknowledgements 
Willem Grootjans is the recipient of an educational grant from Siemens Healthcare, The Hague, The 
Netherlands 
15 
 
 
Conflict of interest 
The authors declare no competing interests 
Ethical considerations 
All procedures performed in this study were in accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards. 
 
 
 
16 
 
References 
[1] Aupérin A, Le Péchoux C, Rolland E et al. Meta-Analysis of Concomitant Versus Sequential 
Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer. J Clin Oncol. 2010;28:2181-90. 
 
[2] Grootjans W, de Geus-Oei L-F, Troost EGC, Visser EP, Oyen WJG, Bussink J. PET in the management of 
locally advanced and metastatic NSCLC. Nat Rev Clin Oncol. 2015;12:395-407. 
 
[3] van Baardwijk A, Bosmans G, Boersma L et al. PET-CT–Based Auto-Contouring in Non–Small-Cell Lung 
Cancer Correlates With Pathology and Reduces Interobserver Variability in the Delineation of the 
Primary Tumor and Involved Nodal Volumes. Int J Radiat Oncol Biol Phys. 2007;68:771-8. 
 
[4] De Ruysscher D, Nestle U, Jeraj R, MacManus M. PET scans in radiotherapy planning of lung cancer. 
Lung Cancer. 2012;75:141-5. 
 
[5] Chirindel A, Adebahr S, Schuster D et al. Impact of 4D-18FDG-PET/CT imaging on target volume 
delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative 
study. Radiother Oncol. 2015;115:335-41. 
 
[6] Kepka L, Socha J. PET-CT use and the occurrence of elective nodal failure in involved field 
radiotherapy for non-small cell lung cancer: A systematic review. Radiother Oncol. 2015;115:151-6. 
 
[7] Aerts HJWL, Bussink J, Oyen WJG et al. Identification of residual metabolic-active areas within NSCLC 
tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation. Lung Cancer. 2012;75:73-
6. 
 
[8] Calais J, Thureau S, Dubray B et al. Areas of High 18F-FDG Uptake on Preradiotherapy PET/CT Identify 
Preferential Sites of Local Relapse After Chemoradiotherapy for Non–Small Cell Lung Cancer. J Nucl Med. 
2015;56:196-203. 
 
[9] Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 
2005;6:112-7. 
 
[10] Usmanij EA, de Geus-Oei L-F, Troost EGC et al. 18F-FDG PET Early Response Evaluation of Locally 
Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy. J Nucl Med. 
2013;54:1528-34. 
 
[11] Im H-J, Pak K, Cheon G et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-
small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241-51. 
 
[12] Yossi S, Krhili S, Muratet J-P, Septans A-L, Campion L, Denis F. Early Assessment of Metabolic 
Response by 18F-FDG PET During Concomitant Radiochemotherapy of Non–Small Cell Lung Carcinoma Is 
Associated With Survival: A Retrospective Single-Center Study. Clin Nucl Med. 2015;40:e215-e21. 
 
[13] Hyun S, Ahn H, Kim H et al. Volume-based assessment by 18F-FDG PET/CT predicts survival in 
patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:50-8. 
 
17 
 
[14] de Geus-Oei L-F, Oyen WJG. Predictive and prognostic value of FDG-PET. Cancer Imaging. 
2008;8:70-80. 
 
[15] Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a survey of image 
segmentation techniques. Eur J Nucl Med Mol Imaging. 2010;37:2165-87. 
 
[16] Lee JA. Segmentation of positron emission tomography images: Some recommendations for target 
delineation in radiation oncology. Radiother Oncol. 2010;96:302-7. 
 
[17] Visser EP, Boerman OC, Oyen WJG. SUV: From Silly Useless Value to Smart Uptake Value. J Nucl 
Med. 2010;51:173-5. 
 
[18] Konert T, Vogel W, MacManus MP et al. PET/CT imaging for target volume delineation in curative 
intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol. 
2015;116:27-34. 
 
[19] Boellaard R, Willemsen AT, Arends B, Visser EP. EARL procedure for assessing PET/CT system 
specific patient FDG activity preparations for quantitative FDG PET/CT studies. Accessed Oct 2015. 
 
[20] van Dalen JA, Hoffmann AL, Dicken V et al. A novel iterative method for lesion delineation and 
volumetric quantification with FDG PET. Nucl Med Commun. 2007;28:485-93. 
 
[21] Daisne J-F, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V. Tri-dimensional automatic 
segmentation of PET volumes based on measured source-to-background ratios: influence of 
reconstruction algorithms. Radiother Oncol. 2003;69:247-50. 
 
[22] Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A Fuzzy Locally Adaptive Bayesian Segmentation 
Approach for Volume Determination in PET. IEEE Trans Med Imaging. 2009;28:881-93. 
 
[23] Arens AIJ, Troost EGC, Hoeben BAW et al. Semiautomatic methods for segmentation of the 
proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their 
relation to clinical outcome. Eur J Nucl Med Mol Imaging. 2014;41:915-24. 
 
[24] van Elmpt W, De Ruysscher D, van der Salm A et al. The PET-boost randomised phase II dose-
escalation trial in non-small cell lung cancer. Radiother Oncol. 2012;104:67-71. 
 
[25] Ingerid Skjei K, Svestad JrG, Erlend Peter Skaug S et al. Validation of dose painting of lung tumours 
using alanine/EPR dosimetry. Phys Med Biol. 2016;61:2243. 
 
[26] Even AJG, van der Stoep J, Zegers CML et al. PET-based dose painting in non-small cell lung cancer: 
Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. 
Radiother Oncol. 2015;116:281-6. 
 
[27] Knudtsen IS, van Elmpt W, Öllers M, Malinen E. Impact of PET reconstruction algorithm and 
threshold on dose painting of non-small cell lung cancer. Radiother Oncol. 2014;113:210-4. 
 
[28] Gao A, Wang S, Fu Z, Sun X, Yu J, Meng X. (18)F-FDG avid volumes on pre-radiotherapy FDG PET as 
boost target delineation in non-small cell lung cancer. Int J Clin Exp Med. 2015;8:7561-8. 
18 
 
 
[29] Nygård L, Vogelius IR, Fischer BM et al. Early lesion-specific 18F-FDG PET response to chemotherapy 
predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiother Oncol. 
2016;118:460-4. 
 
[30] van Diessen JNA, Chen C, van den Heuvel MM, Belderbos JSA, Sonke J-J. Differential analysis of local 
and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent 
chemoradiotherapy. Radiother Oncol. 2016;118:447-52. 
 
 Figure legends 
 
Figure 1| Box and whisker plots of summed total lesion glycolysis (TLG) of the primary tumor and the lymph nodes 
in pre-treatment and interim 
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scans obtained 
with different segmentation algorithms. Bottom and top of each box are lower and upper quartiles. The horizontal 
line near middle of the box is median. Whiskers are drawn down to the 5% percentile up to the 95% percentile, 
while the outliers are indicated by a dot. T40= Fixed level threshold segmentation at 40% of the maximum 
standardized uptake value (SUVmax), T50= Fixed level threshold segmentation at 50% of SUVmax, RTL= Relative level 
thresholding, SBR= Signal-to-background segmentation, FLAB=Fuzzy locally adaptive Bayesian segmentation.  
Figure 2|Baseline (a+c) and early response monitoring (ERM) (b+d) 
18
F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) images of two non-small cell lung cancer (NSCLC) patients. The first patient (a+b) showed a good 
response to treatment on both the primary tumour and lymph nodes. Although the primary tumour of the second 
patient (c+d) showed a good response to treatment, there was a limited response considering the lymph nodes, 
with more positive lymph nodes in the ERM PET. The mean summed fractional decrease of total lesion glycolysis 
;ΔTLGͿ of the first patieŶt for the differeŶt segŵeŶtatioŶ ŵethods ǁas ϳϲ±ϲ%, ǁith a progressioŶ free survival 
;PFSͿ of ϭϭ ŵoŶths aŶd overall survival ;OSͿ of Ϯϰ ŵoŶths. For the seĐoŶd patieŶt, ŵeaŶ ΔTLG ǁas ϯϴ±ϲ% ǁith a 
PFS and OS of 7 and 21 months, respectively. 
 
Tables and legends  
Table 1| Patients Characteristics 
Characteristics of patient population 
Male(Female) 18(9) 
Median age (range) [y] 58 (42-77) 
  
Histological type  
  
Non-small cell lung cancer (NSCLC) 60 
Squamous cell carcinoma 10 
Adenocarcinoma 14 
NSCLC not otherwise specified 3 
  
Disease stage
c
  
IIIA 520 
IIIB 7 
  
Performance-score (ECOG)  
0 19 
1 7 
  
Smoking status  
Current smoker 11 
Former smoker 16 
  
  
Lesion location  
Right upper lobe 11 
Right middle lobe 4 
Right lower lobe 2 
Left upper lobe 8 
Left lower lobe 2 
  
Pre-treatment PET acquisition  
Number of bed positions 7-8 
Administered FDG activity [MBq] 267±48 
Incubation time [min] 75±7.5 
Acquisition time per bed position [min] 4 
  
Interim PET acquisition  
Number of bed positions 4-5 
Administered FDG activity 269±49 
Incubation time 78±8.0 
Acquisition time per bed position [min] 4 
 
Data are reported as mean±standard deviation. PET=positron emission tomography, FDG=
18
F-fluorodeoxyglycose 
Table
Table 2| Hazard ratios (HRs) and 95% confidence interval (CI) of pre-treatment primary tumour total lesion 
glycolysis (TLGTͿ aŶd relative TLG deĐrease ;ΔTLGT) between pre-treatment and interim 18F-fluorodeoxyglucose 
(FDG) positron emission tomography (PET) in a univariate Cox regression analysis for progression-free survival 
(PFS) and overall-survival (OS).  
 HR (95% CI) per unit change for PFS Significance level 
Pre-treatment TLGT 
T40 
T50 
RTL 
SBR 
FLAB 
 
1.002 (1.000 – 1.004) 
1.002 (1.000 – 1.004) 
1.002 (1.000 – 1.004) 
1.002 (1.000 – 1.003) 
1.002 (1.000 – 1.003) 
 
0.02* 
0.03* 
0.03* 
0.02* 
0.03* 
ΔTLGT 
T40 
T50 
RTL 
SBR 
FLAB 
 
1.02 (1.003 – 1.03)  
1.02 (1.003 – 1.03)  
1.02 (1.003 – 1.04)  
1.02 (1.004 – 1.04)  
1.02 (1.000 – 1.04) 
 
0.03* 
0.03* 
0.03* 
0.02* 
0.07 
 HR (95% CI) per unit change for OS Significance level 
Pre-treatment TLGT 
T40 
T50 
RTL 
SBR 
FLAB 
 
1.002 (1.001 – 1.004) 
1.003 (1.001 – 1.004) 
1.002 (1.001 – 1.004) 
1.002 (1.001 – 1.003) 
1.002 (1.001 – 1.003) 
 
0.004* 
0.005* 
0.004* 
0.004* 
0.006* 
ΔTLGT 
T40 
T50 
RTL 
SBR 
FLAB 
 
1.02 (1.00 – 1.03)  
1.02 (1.00 – 1.03)  
1.02 (1.00 – 1.03)  
1.02 (1.00 – 1.03)  
1.01 (0.99 – 1.03) 
 
0.05 
0.02* 
0.08 
0.04*  
0.3 
 
T40= fixed level threshold at 40% of the maximum standardized uptake voxel (SUVmax), T50= fixed level threshold 
at 50% of SUVmax, RTL=relative level thresholding, SBR=signal-to-background-ratio, FLAB=fuzzy locally adaptive 
BayesiaŶ segŵeŶtatioŶ. StatistiĐal sigŶifiĐaŶĐe is iŶdiĐated ďy aŶ asterisk ͚*͛. 
 
 
 
 
 
 
 
 
Table 3| Hazard ratios (HRs) and 95% confidence interval (CI) of pre-treatment summed total lesion glycolysis 
(TLGSͿ aŶd relative TLG deĐrease ;ΔTLGS) between pre-treatment and interim 18F-fluorodeoxyglucose (FDG) 
positron emission tomography (PET) in a univariate Cox regression analysis for progression-free survival (PFS) and 
overall-survival (OS). TLGS is the sum  of primary tumour TLG (TLGT) and lymph node TLG (TLGLN).  
 HR (95% CI) per unit change for PFS Significance level 
Pre-treatment TLGS 
T40 
T50 
RTL 
SBR 
FLAB 
 
1.003 (1.001 – 1.005) 
1.003 (1.001 – 1.005) 
1.003 (1.001 – 1.005) 
1.002 (1.001 – 1.004) 
1.002 (1.001 – 1.004) 
 
0.002* 
0.004* 
0.003* 
0.004* 
0.004* 
ΔTLG  
T40 
T50 
RTL 
SBR 
FLAB 
 
1.02 (1.00 – 1.05) 
1.03 (1.02 – 1.05)   
1.01 (1.00 – 1.02) 
1.04 (1.02 – 1.06) 
1.02 (1.00 – 1.04) 
 
0.03* 
0.001* 
0.2 
0.001* 
0.04* 
 HR (95% CI) per unit change for OS Significance level 
Pre-treatment TLGS 
T40 
T50 
RTL 
SBR 
FLAB 
 
1.003 (1.001 – 1.004) 
1.003 (1.001 – 1.005) 
1.003 (1.001 – 1.005) 
1.002 (1.001 – 1.004) 
1.002 (1.001 – 1.004) 
 
0.001* 
0.002* 
0.001* 
0.001* 
0.002* 
 
ΔTLGS 
T40 
T50 
RTL 
SBR 
FLAB 
 
1.01 (1.00 – 1.03) 
1.02 (1.00 – 1.04)   
1.00 (1.00 – 1.01) 
1.02 (1.00 – 1.04) 
1.01 (1.00 – 1.03) 
 
0.4 
0.02* 
0.9 
0.03* 
0.02* 
 
T40= fixed level threshold at 40% of the maximum standardized uptake voxel (SUVmax), T50= fixed level threshold 
at 50% of SUVmax, RTL=relative level thresholding, SBR=signal-to-background-ratio, FLAB=fuzzy locally adaptive 
BayesiaŶ segŵeŶtatioŶ. StatistiĐal sigŶifiĐaŶĐe is iŶdiĐated ďy aŶ asterisk ͚*͛. 
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